Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing SolutionsBusiness Wire • 10/17/22
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening ProgramsBusiness Wire • 10/12/22
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint InhibitorsBusiness Wire • 07/20/22
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International ConferenceBusiness Wire • 05/12/22
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term LoanBusiness Wire • 04/11/22
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With CancerBusiness Wire • 03/29/22